Full Press Release Details
Telix at SNMMI 2026
Telix is in Los Angeles this week for the SNMMI 2026 Annual Meeting.
This year’s program features seven abstracts from across Telix’s oncology portfolio, including three oral presentations exploring novel imaging approaches in clear cell renal cell carcinoma, thyroid cancer and bone marrow dosimetry.
Poster presentations will also cover prostate cancer imaging (BiPASS™), kidney cancer therapy (LUTEON), recurrent glioblastoma therapy (IPAX BrIGHT), and discovery-stage radiopharmaceutical science.
Meet us at Booth #745 to connect with Telix and learn more about our theranostic pipeline, commercial portfolio and manufacturing capabilities.
TLX250-Px, TLX250-Tx, TLX400-Px and TLX101-Tx have not received marketing authorizations in any jurisdiction.
Abstract presentations
SS11 Genitourinary Diagnosis and Imaging SS Room 3 | May 31 | 12:40 PM – 12:50 PM PDT
SS24 Oncology Clinical Diagnosis and Therapy Scientific Session: Endocrine and Head and Neck
SS Room 4 |June 1 | 1:45 PM – 1:55 PM PDT
IS09 Advanced Methodology of Data Analysis and Dosimetry IS Room | Jun 2 | 11:30 AM – 11:40 AM PDT
MTA03 Oncology Clinical Diagnosis and Therapy Scientific Session Screen 53 | May 31 | 5:30 PM – 6:15 PM PDT
MTA06 Oncology Clinical Diagnosis and Therapy Scientific Session Screen 44 | June 1 | 10:30 AM – 11:15 AM PDT
MTA06 Oncology Clinical Diagnosis and Therapy Scientific Session Screen 18 | June 1 | 10:30 AM – 11:15 AM PDT
MTA07 Educational Exhibits Meet the Author Session Science Pavilion | Jun 1 | 1:15 PM – 2:00 PM PDT
MTA08 Neurosciences Screen 42 | June 1 | 2:45 PM – 3:30 PM PDT
MTA11 Oncology: Discovery & Translational Meet the Author Session Screen 43 | June 2 | 11:30 AM – 12:15 PM PDT